These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21683980)

  • 1. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
    Minner S; Kraetzig F; Tachezy M; Kilic E; Graefen M; Wilczak W; Bokemeyer C; Huland H; Sauter G; Schlomm T
    Hum Pathol; 2011 Dec; 42(12):1946-52. PubMed ID: 21683980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
    Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
    Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
    Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
    Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
    Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
    Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
    J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
    Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
    J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
    Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
    Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH
    J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
    Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
    Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
    Xu C; Jung M; Burkhardt M; Stephan C; Schnorr D; Loening S; Jung K; Dietel M; Kristiansen G
    Prostate; 2005 Feb; 62(3):224-32. PubMed ID: 15389793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
    Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
    J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated leukocyte cell adhesion molecule (CD166): an "inert" cancer stem cell marker for non-small cell lung cancer?
    Tachezy M; Zander H; Wolters-Eisfeld G; Müller J; Wicklein D; Gebauer F; Izbicki JR; Bockhorn M
    Stem Cells; 2014 Jun; 32(6):1429-36. PubMed ID: 24501004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.